Floatz logo

bt1718

Oesophageal Cancer

Cancer Research UKprotein_peptidePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

131 Active assets in the Oesophageal Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 4BB
Benadryl
Ciusss de L'Est de l'Île de Montréal
Phase 3B
Pembrolizumab
Essen Biotech
Phase 3B
Cyclophosphamide
Sutro Biopharma, Inc.
Phase 3B

View all 50 →

Same molecule, other indications

bt1718 is also rated in:

Advanced Solid TumoursDormant
CCC
Indicative ·
50 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →